

UNITED STATES PATENT AND TRADEMARK OFFICE

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

AQUESTIVE THERAPEUTICS, INC.

Petitioner

v.

NEURELIS, INC.

Patent Owner

---

IPR2019-00451

U.S. Patent No. 9,763,876

---

**DECLARATION OF DANIEL P. WERMELING, Pharm.D.**

**TABLE OF CONTENTS**

I. BASIS FOR OPINION .....2

II. RELEVANT CONSIDERATIONS.....13

A. POSA .....18

1. Ethanol Versus Dehydrated Ethanol.....20

III. QUALIFICATIONS AND BACKGROUND .....22

IV. GROUNDS FOR INVALIDATING THE ‘876 PATENT CLAIMS .....26

V. THE HISTORY OF INTRANASAL BENZODIAZEPINE DELIVERY ..29

A. Summary .....29

B. Introduction.....30

C. Nasal Anatomy As Related to Intranasal Drug Delivery .....32

VI. COMMERCIAL SUCCESS AND LONG-FELT NEED IN THE DESIGN  
OF NASAL PRODUCTS FOR SYSTEMIC DRUG ADMINISTRATION  
INCLUDES TECHNICAL CONSIDERATIONS AS WELL AS MARKETING  
CONSIDERATIONS .....36

A. Exclusion of Market Considerations.....36

B. Patent Owner’s Expert Testified That he was Unaware of the Composition of Patent Owner’s Intranasal Diazepam Spray, Valtoco, and He Could Not Answer Whether Valtoco Satisfied any Long-Felt Need.....37

C. Commercial Success Factors – Formulation and Commercial Considerations.....40

1. Product Design Considerations.....42

2. Pharmacokinetics And Pharmacodynamics Of Nasal Benzodiazepines In Healthy Volunteers .....49

D. Prior Art Experience With Intranasal Delivery Of Benzodiazepines For Treatment Of Seizures Prior To 2009.....53

VII. THE PATHWAY TO FORMULATING THE SOLUTION .....58

1. There Were Many Nasal Delivery Systems And Many Non-Technical Problems To Their Commercialization.....61

2. Background In The Intranasal Art .....72

VIII. GWOZDZ, MEEZAN’962 and CARTT’784 MAKE ALL THE CLAIMS OF THE ‘876 PATENT OBVIOUS. ....84

A. Gwozdz (Exhibit 1014).....85

1. A POSA Would Have Used Gwozdz’ Disclosure of Ternary Co-Solvent Systems Such as Tocopherol+ Ethanol+Benzyl Alcohol, and Gwozdz’ Disclosure is Not Limited to Administration to One Nostril.....86

(a) A POSA Would Expect that a Ternary Co-Solvent System (Tocopherol+Ethanol+Benzyl Alcohol) Could Solubilize More Diazepam Than a Binary Co-Solvent System (Tocopherol+Ethanol).....86

(b) Gwozdz’ Ternary Co-Solvent Diazepam Solution in a Reduced Concentration Can be Administered to Both Nostrils to Deliver the Same Amount of Diazepam and Avoid Possibility of Precipitating Out .....91

2. The Combination of Ethanol and Benzyl Alcohol and Diazepam for Use in Treating Seizures in Humans was Well Known .....92

B. A POSA HAD THE MOTIVATION TO COMBINE THE TEACHINGS OF GWOZDZ, MEEZAN’962 AND CARTT’784.....98

1. Contrary to Patent Owner’s argument, a POSA would not be deterred from applying Meezan’962’s teaching of the use of alkyl glycosides in connection with non-aqueous solutions.....99

2. Contrary to Patent Owner’s argument, a POSA would not be deterred from applying the teachings of Cartt’784 to the disclosures of Gwozdz. Rather, the POSA would be motivated to combine the two references. ....100

IX. The ‘558 Provisional Application’s (Exhibit 1008) incorporation by reference of the Sigma Catalogue (Exhibit 2006) does not convey to a POSA either a directed disclosure of alkyl glycosides as absorption enhancer or even that the inventors knew that alkyl glycosides would necessarily work as such. ....103

X. THERE ARE NO UNEXPECTED RESULTS OR CRITICALITY ASSOCIATED WITH ANY OF THE RECITED ALCOHOL RANGES OR AMOUNTS .....108

A. A POSA Would Have Known that Tocopherols Contribute to Increased Bioavailability.....111

B. A POSA Would Have Expected Solutions to Have Higher Bioavailabilities Than Suspensions.....112

C. Diazepam is 100% Bioavailable For Nasal and Oral Absorption .....113

D. The Table 11-3 data for the solution is not evidence of any criticality associated with the recited claim ranges for ethanol and benzyl alcohol.....117

1. Nasally-Administered Diazepam’s 100% Nas-Oral Bioavailability .....120

2. No Data Regarding Bioavailability of Solutions Having Benzyl Alcohol and Ethanol Other Than in Table 11-3 (10.5% benzyl alcohol and 18.07% ethanol (dehydrated)).....121

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.